M

Michigan State University | Department of Neurology

Research site
(Unclaimed)
Location
804 Service Road, Suite A212 Clinical Center, East Lansing, Michigan, United States of America

Site insights

Top conditions

Top treatments

Bapineuzumab
cyclophosphamide
Levodopa
Carbidopa
Tamoxifen
doxorubicin hydrochloride
Cyclophosphamide
Paclitaxel
YM872
Isradipine

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 145 total trials

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and toler...

Enrolling
Focal Onset Seizures
Drug: XEN1101
Drug: Placebo

This study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to preve...

Active, not recruiting
Haemophilia A With Inhibitors
Haemophilia A
Drug: NNC0365-3769 (Mim8) PPX

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan
Locations recently updated

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling
High-risk Transient Ischemic Attack
Acute Non-cardioembolic Ischemic Stroke
Drug: Asundexian (BAY2433334)
Drug: Placebo

This study will evaluate the long term safety, tolerability, PK, and efficacy of XEN1101 25 mg QD taken orally in subjects with Focal Onset Seizures...

Invitation-only
Tonic-Clonic Seizures
Focal Epilepsy
Drug: XEN1101

The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experiment...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Placebo
Drug: Atezolizumab

This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placeb...

Enrolling
Parkinson Disease
Dyskinesia, Drug-Induced
Drug: Dipraglurant
Drug: Placebo

This is a multi-center, randomized, double-blind, double-dummy, active controlled clinical Study. Following a screening period, eligible subjects wil...

Active, not recruiting
Parkinson's Disease
Combination Product: ND0612 Solution for SC infusion
Drug: Placebo for Oral IR-LD/CD

The primary objective is to understand the utility of Personal KinetiGraph movement recording system data in the clinical management of Parkinson's d...

Active, not recruiting
Parkinson Disease
Device: Personal KinetiGraph™ (PKG™)

Researchers are looking for a better way to treat people who have hemophilia A. Hemophilia A is a genetic bleeding disorder that is caused by the lac...

Enrolling
Prophylaxis of Bleeding
Hemophilia A
Biological: Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).

This trial is intended to study the safety and effectiveness of an new anti-epileptic drug (AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures....

Enrolling
Primary Generalized Epilepsy
Drug: Placebo
Drug: Cenobamate

At present, widespread use of the human milk-based caloric supplement (cream) has not occurred, particularly in infants with bronchopulmonary dysplas...

Active, not recruiting
Bronchopulmonary Dysplasia
Dietary Supplement: Cream Supplement group

Trial sponsors

M
C
N
B
Baxalta logo
Pfizer logo
J
National Cancer Institute (NCI) logo
A
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems